Does ipamorelin raise cortisol like older peptides?

In the primary pharmacology work (Raun et al. 1998), ipamorelin released growth hormone without meaningfully raising cortisol, ACTH, or prolactin at GH-releasing doses, which is the basis for its selective reputation. That finding comes from preclinical and early human pharmacology, not from a large safety trial, so it describes a mechanism rather than a proven long-term safety margin.

What are the most commonly reported ipamorelin side effects?

The effects reported most often are water retention and mild swelling, transient headache, a flushing or head-rush sensation soon after dosing, injection-site reactions, and increased appetite. None is documented in a large controlled human trial of ipamorelin; they are small-study observations and extrapolation from the growth-hormone-secretagogue class.

Can ipamorelin affect blood sugar?

Plausibly. Anything that raises growth hormone and IGF-1 can reduce insulin sensitivity and raise blood glucose, and a 2018 review found raised blood glucose to be the most consistent metabolic signal across growth-hormone secretagogues. The size of that effect for ipamorelin specifically has not been established in long-term human studies.

Is ipamorelin FDA-approved?

No. Ipamorelin has no approved indication. It reached Phase 2 for postoperative ileus and did not advance to approval. Material sold as ipamorelin is labeled for research use, is not held to pharmaceutical quality standards, and has unverified purity.

Why does PepVise not list an ipamorelin dose?

Because a dose from a website is not a substitute for a prescription from a licensed clinician working within a regulated pathway, and because the numbers repeated online are extrapolated from animal work and forum convention, not from a human dose-finding trial. We describe what has been published. We do not tell readers what to administer.

Explainer· Compounds

Ipamorelin side effects, what the data shows

By The PepVise Editorial Team · Reviewed July 15, 2026 · 10 min read

Ipamorelin side effects read through the evidence: a selective GH secretagogue that spares cortisol and prolactin, the reported class effects on water retention and glucose, and why the human safety record is thin.

Mechanism explainers on PepVise aim for textbook-level clarity without the textbook's refusal to commit to a reading.

Frequently asked

What readers ask us next.

Does ipamorelin raise cortisol like older peptides?: In the primary pharmacology work (Raun et al. 1998), ipamorelin released growth hormone without meaningfully raising cortisol, ACTH, or prolactin at GH-releasing doses, which is the basis for its selective reputation. That finding comes from preclinical and early human pharmacology, not from a large safety trial, so it describes a mechanism rather than a proven long-term safety margin.
What are the most commonly reported ipamorelin side effects?: The effects reported most often are water retention and mild swelling, transient headache, a flushing or head-rush sensation soon after dosing, injection-site reactions, and increased appetite. None is documented in a large controlled human trial of ipamorelin; they are small-study observations and extrapolation from the growth-hormone-secretagogue class.
Can ipamorelin affect blood sugar?: Plausibly. Anything that raises growth hormone and IGF-1 can reduce insulin sensitivity and raise blood glucose, and a 2018 review found raised blood glucose to be the most consistent metabolic signal across growth-hormone secretagogues. The size of that effect for ipamorelin specifically has not been established in long-term human studies.
Is ipamorelin FDA-approved?: No. Ipamorelin has no approved indication. It reached Phase 2 for postoperative ileus and did not advance to approval. Material sold as ipamorelin is labeled for research use, is not held to pharmaceutical quality standards, and has unverified purity.
Why does PepVise not list an ipamorelin dose?: Because a dose from a website is not a substitute for a prescription from a licensed clinician working within a regulated pathway, and because the numbers repeated online are extrapolated from animal work and forum convention, not from a human dose-finding trial. We describe what has been published. We do not tell readers what to administer.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min read

Compounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min read

Compounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.